Literature DB >> 31632765

Respecting your elders: osimertinib demonstrates preferential activity in elderly patients with T790M positive non-small cell lung cancers.

Hiromichi Ebi1,2,3, Sosipatros Boikos4, Anthony C Faber5.   

Abstract

Entities:  

Year:  2019        PMID： 31632765      PMCID： PMC6783766          DOI： 10.21037/jtd.2019.08.122

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  17 in total

1.  Absence of EGFR C797S Mutation in Tyrosine Kinase Inhibitor-Naïve Non-Small Cell Lung Cancer Tissues.

Authors:  Igor P Oscorbin; Alexandra S Shadrina; Vadim V Kozlov; Vladimir E Voitsitsky; Maxim L Filipenko
Journal:  Pathol Oncol Res       Date:  2019-06-26       Impact factor: 3.201

2.  Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.

Authors:  Raffaella Sordella; Daphne W Bell; Daniel A Haber; Jeffrey Settleman
Journal:  Science       Date:  2004-07-29       Impact factor: 47.728

3.  The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor.

Authors:  Nadia Godin-Heymann; Lindsey Ulkus; Brian W Brannigan; Ultan McDermott; Jennifer Lamb; Shyamala Maheswaran; Jeffrey Settleman; Daniel A Haber
Journal:  Mol Cancer Ther       Date:  2008-04       Impact factor: 6.261

4.  ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer.

Authors:  Filippo de Marinis; Yi-Long Wu; Gilberto de Castro; Gee-Chen Chang; Yuh-Min Chen; Byoung Chul Cho; Helano C Freitas; Liyan Jiang; Sang-We Kim; Claudio Martin; Giulio Metro; Mariano Provencio; Johan Vansteenkiste; David Vicente; Qing Zhou; Miguel F Miranda; Nicolaas A Bakker; James R Rigas; Parneet K Cheema
Journal:  Future Oncol       Date:  2019-07-24       Impact factor: 3.404

5.  Efficacy and Safety Data of Osimertinib in Elderly Patients with NSCLC Who Harbor the EGFR T790M Mutation After Failure of Initial EGFR-TKI Treatment.

Authors:  Hiromi Furuta; Takehiro Uemura; Tatsuya Yoshida; Makiko Kobara; Teppei Yamaguchi; Naohiro Watanabe; Junichi Shimizu; Yoshitsugu Horio; Hiroaki Kuroda; Yukinori Sakao; Yasushi Yatabe; Toyoaki Hida
Journal:  Anticancer Res       Date:  2018-09       Impact factor: 2.480

6.  AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

Authors:  Pasi A Jänne; James Chih-Hsin Yang; Dong-Wan Kim; David Planchard; Yuichiro Ohe; Suresh S Ramalingam; Myung-Ju Ahn; Sang-We Kim; Wu-Chou Su; Leora Horn; Daniel Haggstrom; Enriqueta Felip; Joo-Hang Kim; Paul Frewer; Mireille Cantarini; Kathryn H Brown; Paul A Dickinson; Serban Ghiorghiu; Malcolm Ranson
Journal:  N Engl J Med       Date:  2015-04-30       Impact factor: 91.245

7.  Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M-Positive Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment: A Phase II Trial.

Authors:  Akira Nakao; Osamu Hiranuma; Junji Uchino; Chikara Sakaguchi; Toshiyuki Kita; Noriya Hiraoka; Tamotsu Ishizuka; Yutaka Kubota; Masayuki Kawasaki; Yasuhiro Goto; Hisao Imai; Noboru Hattori; Keita Nakatomi; Hidetaka Uramoto; Kiyoaki Uryu; Minoru Fukuda; Yasuki Uchida; Toshihide Yokoyama; Masaya Akai; Tadashi Mio; Seiji Nagashima; Yusuke Chihara; Nobuyo Tamiya; Yoshiko Kaneko; Takako Mouri; Tadaaki Yamada; Kenichi Yoshimura; Masaki Fujita; Koichi Takayama
Journal:  Oncologist       Date:  2019-01-16

8.  Impact of clinical features on the efficacy of osimertinib therapy in patients with T790M-positive non-small cell lung cancer and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors.

Authors:  Yasuhiro Kato; Yukio Hosomi; Kageaki Watanabe; Makiko Yomota; Shoko Kawai; Yusuke Okuma; Kaoru Kubota; Masahiro Seike; Akihiko Gemma; Tatsuru Okamura
Journal:  J Thorac Dis       Date:  2019-06       Impact factor: 2.895

9.  Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.

Authors:  Glenwood Goss; Chun-Ming Tsai; Frances A Shepherd; Lyudmila Bazhenova; Jong Seok Lee; Gee-Chen Chang; Lucio Crino; Miyako Satouchi; Quincy Chu; Toyoaki Hida; Ji-Youn Han; Oscar Juan; Frank Dunphy; Makoto Nishio; Jin-Hyoung Kang; Margarita Majem; Helen Mann; Mireille Cantarini; Serban Ghiorghiu; Tetsuya Mitsudomi
Journal:  Lancet Oncol       Date:  2016-10-14       Impact factor: 41.316

10.  AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

Authors:  Darren A E Cross; Susan E Ashton; Serban Ghiorghiu; Cath Eberlein; Caroline A Nebhan; Paula J Spitzler; Jonathon P Orme; M Raymond V Finlay; Richard A Ward; Martine J Mellor; Gareth Hughes; Amar Rahi; Vivien N Jacobs; Monica Red Brewer; Eiki Ichihara; Jing Sun; Hailing Jin; Peter Ballard; Katherine Al-Kadhimi; Rachel Rowlinson; Teresa Klinowska; Graham H P Richmond; Mireille Cantarini; Dong-Wan Kim; Malcolm R Ranson; William Pao
Journal:  Cancer Discov       Date:  2014-06-03       Impact factor: 39.397
View more
  1 in total

1.  Effect of CT-guided microwave ablation for non-small cell lung cancer combined with severe chronic obstructive pulmonary disease.

Authors:  Zhenhua Rong; Yongqi Ji; Faliang Dai; Fangfang Zhang; Yan Jiao; Yixing Liu
Journal:  Am J Transl Res       Date:  2021-11-15       Impact factor: 4.060
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.